参附强心丸治疗肺源性心脏病最佳切入点量效关系研究

目的通过比较不同用药时间及剂量参附强心丸对肺源性心脏病(肺心病)模型大鼠的影响,明确参附强心丸治疗实验性肺心病大鼠最佳用药切入点。方法通过混合烟熏联合ip野百合碱法制备大鼠肺心病模型,对比参附强心丸不同给药时间、给药剂量对大鼠右心肥厚指数、肺泡平均内衬间隔、肺泡数、气道炎症病理学评分、基质金属蛋白酶-9(MMP-9)的影响。结果与模型组相比,参附强心丸治疗高、低剂量组大鼠右心肥厚指数显著降低、肺泡数显著增多、血清心房钠尿肽(ANP)水平降低、心肺组织MMP-9水平下降(P0.05),其中治疗高剂量组效果显著。结论参附强心丸短期用药即治疗给药2周,在降低右心肥厚指数、抑制气道反应等方面均优于长期用药即预防给药4周,且存在一定量效关系。

Quantitative effect relationship of best entry point of Shenfu Qiangxin Pills in treatment of corpulmonale

Objectives To compare the influences of Shenfu Qiangxin Pillsat different medication time and dosage on corpulmonale model rats, and define the best drug use entry point of Shenfu Qiangxin Pills in rats with corpulmonale. Methods The smudging combined with ip rattlebush alkaline were used to prepare rats corpulmonale model, and the effects of Shenfu Qiangxin Pills at different drug administration time and dosage on right ventricle hypertrophy index, alveolar mean linear intercept, alveolar numbers, airway inflammation pathological scores, and matrix metalloproteinase-9 (MMP-9) in rats were investigated. Results Comparing with the model group, the right ventricle hypertrophy index of rats in high-and low-dosage groups of Shenfu Qiangxin Pills was significantly reduced. Alveolar number was significantly increased. Serum ANP level was reduced. Cardiopulmonary MMP-9 level was reduced (P < 0.05). The effects in the high-dosage group was significant. Conclusion The short-term drug administration of Shenfu Qiangxin Pills for two weeks was superior to long-term precaution drug administration for four weeks by reducing right ventricle hypertrophy index and inhibiting airway reaction, and existed dose-effect relationship.